SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-24-000449
Filing Date
2024-05-08
Accepted
2024-05-08 19:55:13
Documents
7
Group Members
ORBIMED CAPITAL GP V LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 9 ss3362183_sc13da.htm SC 13D/A 73292
2 JOINT FILING AGREEMENT ss3362183_ex9901.htm EX-99.1 5164
3 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK ss3362183_ex9902.htm EX-99.2 76015
4 WARRANT TO PURCHASE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ss3362183_ex9903.htm EX-99.3 163556
5 GRAPHIC image_001.jpg GRAPHIC 1863
6 GRAPHIC image_002.jpg GRAPHIC 1863
7 GRAPHIC image_003.jpg GRAPHIC 1863
  Complete submission text file 0000947871-24-000449.txt   327763
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Subject) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89443 | Film No.: 24928063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)